Stockscreener 앱 받기
0.8073
0.98%
0.0078
iBio Inc 주식(IBIO)의 최신 뉴스
Insiders Who Purchased US$655.0k Of iBio Stock May Not Have Expected 23% Tumble - simplywall.st
Insider Buyers At iBio Likely Disappointed With 23% Slide - Yahoo Finance
Chardan Capital Has Pessimistic View of iBio FY2025 Earnings - Defense World
Chardan Capital Has Bearish Outlook for iBio FY2025 Earnings - Defense World
Would I Consider iBio Inc (NASDAQ: IBIO) Stock Any Time In The Future? - Stocksregister
Balance Sheet Dive: iBio Inc (IBIO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
iBio (IBIO) Rating Maintained at Buy by Chardan Capital | IBIO S - GuruFocus
iBio (IBIO) Rating Maintained at Buy by Chardan Capital | IBIO Stock News - GuruFocus
iBio’s (IBIO) Buy Rating Reaffirmed at Chardan Capital - Defense World
iBio (NYSEMKT:IBIO) Shares Down 1.9% – Time to Sell? - Defense World
iBio announces new preclinical data for Activin E antibody - TipRanks
Chardan Capital Maintains Buy Rating for iBio (IBIO) with $5 Pri - GuruFocus
Chardan Capital Maintains Buy Rating for iBio (IBIO) with $5 Price Target | IBIO Stock News - GuruFocus
iBio (IBIO) Reports Promising Results from Activin E Antibody Study | IBIO Stock News - GuruFocus
iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model - The Manila Times
iBio’s First-in-Class Activin E Antibody Achieves >26% Fat - GlobeNewswire
Revolutionary Obesity Treatment Achieves 77% Fat Reduction While Preserving Muscle Mass, Outperforms GLP-1s - Stock Titan
iBio, Inc. Reports Strong Q3 2025 Progress - TipRanks
iBio, Inc. (NYSE:IBIO) Shares Purchased by Geode Capital Management LLC - Defense World
iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Down 20.9% in April - Defense World
IBio Reports Fiscal Third Quarter 2025 Financial Results - marketscreener.com
iBio (IBIO) Secures Financial Growth and Advances Drug Pipeline - GuruFocus
iBio (IBIO) Secures Financial Growth and Advances Drug Pipeline | IBIO Stock News - GuruFocus
iBio Reports Fiscal Third Quarter 2025 Financial Results | IBIO Stock News - GuruFocus
iBio Reports Fiscal Third Quarter 2025 Financial Results - The Manila Times
iBio, Inc. Reports Q3 2025 Financial Results and Corporate Progress Following Nasdaq Listing - Nasdaq
iBio Reports Strong Pipeline Data and Nasdaq Uplisting as Q3 R&D Investment Doubles - Stock Titan
Take off with iBio Inc (IBIO): Get ready for trading - Sete News
Analyzing iBio Inc (IBIO) After Recent Trading Activity - knoxdaily.com
iBio Raises $6.2 Million Through Warrant Inducement Transaction - GuruFocus
iBio Raises $6.2 Million Through Warrant Inducement Transaction | IBIO Stock News - GuruFocus
Biotech Firm iBio Raises $6.2M in Fresh Capital: New Warrants Issued at $0.86 - Stock Titan
What to expect from iBio Inc’s (IBIO) current quarter earnings? - uspostnews.com
Teck Resources Ltd [TECK] Insider Activity: An Update for Investors - knoxdaily.com
iBio (NYSE:IBIO) Trading Up 14.3% – Should You Buy? - Defense World
An Overview of iBio Inc (NASDAQ: IBIO)’s Stock Performance and Outlook - Marketing Sentinel
Analytical Overview: TMC the metals company Inc (TMC)’s Ratios Tell a Financial Story - DWinneX
Quarterly Snapshot: Quick and Current Ratios for iBio Inc (IBIO) - DWinneX
iBio - The Pharma Letter
AstralBio - The Pharma Letter
iBio Inc (IBIO) expanding its growth trajectory ahead - Sete News
Off-market insider buying at Tantalex Lithium Resource (TTX) - The Globe and Mail
Monitoring iBio Inc (IBIO) after recent insider movements - knoxdaily.com
iBio Enters Licensing Agreement for Obesity Treatment - MSN
In the Green: iBio Inc (IBIO) Closes at 0.70, Up/Down -17.43 from Previous Day - DWinneX
Ibio Inc Enters Exclusive License Agreement With AstralBio - marketscreener.com
iBio Inc (IBIO) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Breaking down IBIO’s current quarter earnings estimates - uspostnews.com
iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio - The Manila Times
Revolutionary AI-Discovered Obesity Drug: iBio Licenses First-Ever Activin E Antibody in $28M Deal - Stock Titan
Porch Group Inc (PRCH) Stock: A Year of Stock Market Dynamics - investchronicle.com
iBio Stock Plummets Despite Positive Data On Weight-Loss Treatment Antibody: Retail Stays Bearish - MSN
iBio stock touches 52-week low at $1.03 amid market challenges By Investing.com - Investing.com South Africa
iBio stock touches 52-week low at $1.03 amid market challenges - Investing.com Australia
iBio (NYSEMKT:IBIO) Stock Price Down 5.5% – Here’s What Happened - Defense World
iBio Highlights Advancements in Obesity Antibody Programs - TipRanks
iBio reports promising data on obesity treatment antibody By Investing.com - Investing.com South Africa
iBio reports promising data on obesity treatment antibody - Investing.com Australia
iBio stock touches 52-week low at $1.42 amid market challenges - Investing.com Australia
0.98%
0.94%
자본화:
|
볼륨(24시간):